The industry is in a difficult position. It is caught between wanting to satisfy the demands of the Trump administration while protecting its most important market and having minimal control over its negotiations with other countries. In other words, it is part stakeholder, participant and spectator. …
Why not construct an off-ramp based on what you were going to do anyway?
June 15, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The effort to change an institution from within, works best when exit is possible
October 15, 2026 - - Latest News -
The medicines gap costing Australian children time they can't get back
October 15, 2026 - - Latest News -
Brain cancer advocates return to Canberra 'to keep that ambition alive'
October 15, 2026 - - Latest News -
Priceline Pharmacy puts its name on the Diamonds as netball rides record growth
October 14, 2026 - - Latest News -
Until the law changes what the committee is instructed to weigh, these processes will deliver nothing
October 14, 2026 - - Latest News -
'Maximising off patent medicines and why the PBS needs a biosimilar strategy'
October 14, 2026 - - Latest News -
Peter Mac taps Sydney manufacturer to test its solid tumour CAR T therapy
October 14, 2026 - - Latest News